Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study

Journal of the National Cancer Institute

Volumn 90, Issue 18, 1998, Pages 1371-1388

  Fisher, Bernard ^a,i   Costantino, Joseph P ^b   Wickerham, D Lawrence ^c   Redmond, Carol K ^b   Kavanah, Maureen ^d   Cronin, Walter M ^b   Vogel, Victor ^b   Robidoux, André ^e   Dimitrov, Nikolay ^f   Atkins, James ^g   Daly, Mary ^b   Wieand, Samuel ^h   Tan Chiu, Elizabeth ⁱ   Ford, Leslie ^j   Wolmark, Norman ^c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g Southeast Cancer Control Consortium   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE;

EID: 0032537990     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.18.1371     Document Type: Article

References (68)

1. Heuson JC. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep 1976;60:1463-6.
2. Mouridsen H, Palshof T, Patterson J, Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978;5:131-41.
3. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA 1979;242:49-52.
4. Margreiter R, Wiegele J. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treat 1984;4:45-8.
5. Jackson IM, Litherland S, Wakeling AE. Tamoxifen and other antiestrogens. In: Powles TJ, Smith IE, editors. Medical management of breast cancer. London (U.K.): Martin Dunitz; 1991. p. 51-61.
6. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1983;1:257-61.
7. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985;1:836-40.
8. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:459-71.
9. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 2:171-5.
10. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
11. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988;57:604-7.
12. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83: 1299-306.
13. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent [editorial]. J Natl Cancer Inst 1991;83:1278-80.
14. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;60:126-31.
15. Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE. Tamoxifen (review). In: Goldberg ME, editor. Pharmacological and biochemical properties of drug substances. Vol 2. Washington (DC): American Pharmaceutical Association; 1979. p. 355-99.
16. Adam HK. Pharmacokinetic studies with Nolvadex. Reviews on Endocrine-Related Cancer 1981;(9 Suppl):131-43.
17. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal anti-oestrogens - receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20:111-20.
18. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987;47:4517-9.
19. Terenius L. Effect of anti-oestrogens on initiation of mammary cancer in the female rat. Eur J Cancer 1971;7:65-70.
20. Jordan VC. Effect of tamoxifen (ICI 46.474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12: 419-24.
21. Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-51.
22. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:339-46.
23. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12: 307-10.
24. Burning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497-9.
25. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
26. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132-5.
27. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
28. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
29. Fisher B, Costantino J. Highlights of the NSABP breast cancer prevention trial. Cancer Control 1997;4:78-86.
30. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-86.
31. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1971; 58:403-17.
32. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials 1984;5:348-61.
33. Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Controlled Clin Trials 1996;17:509-25.
34. Rosner B. Fundamentals of biostatistics. 4th ed. Boston: Duxbury Press; 1995. p. 590-4.
35. Korn EL, Dorey FJ. Applications of crude incidence curves. Stat Med 1992;11:813-29.
36. Radloff LF, The CES-D scale: a self-report depression scale for research in the general public. Appl Psychol Meas 1977;1:385-401.
37. Stewart AL, Ware JE Jr, editors. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham (NC): Duke University Press; 1992.
38. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 1984;73:1381-7.
39. Szarka CE, Grana G, Engstrom PF. Chemoprevention of cancer. Curr Probl Cancer 1994;18:6-79.
40. Bernstein L, Ross RK, Henderson BE. Prospects for the primary prevention of breast cancer. Am J Epidemiology 1992;135:142-52.
41. Lippman SM, Benner SE, Hong WK. Chemoprevention. Strategies for the control of cancer. Cancer 1993;72(3 Suppl):984-90.
42. Prentice RL, Kakar F, Hursting S, Sheppard L, Klein R, Kushi LH. Aspects of the rationale for the Women's Health Trial. J Natl Cancer Inst 1988;80: 802-14.
43. Veronesi U, De Palo G, Costa A, Formelli F, Marubini E, Del Vecchio M. Chemoprevention of breast cancer with retinoids. J Natl Cancer Inst Monogr 1992;12:93-7.
44. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992;69: 1174-81.
45. Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993;68:156-61.
46. Giri DD, Dundas SA, Nottingham JF, Underwood JC. Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study. Histopathology 1989;15:575-84.
47. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 1990;94:533-7.
48. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
49. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trial Breast Group. BMJ 1995;311:977-80.
50. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997; 89:776-82.
51. Melton LJ 3d, Eddy DM, Johnston CC Jr. Screening for osteoporosis. Ann Intern Med 1990;112:516-28.
52. Fisher B, Dignam J, Bryant J, DeCillis A. Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
53. Stearns V, Gelmann EP. Does tamoxifen cause cancer in human? J Clin Oncol 1998;16:779-92.
54. ACOG committee on Gynecologic Practice. Committee opinion. Washington (DC): The American College of Obstetrics and Gynecologists; 1996;169:1-3.
55. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1946;32A: 1464-76.
56. Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 1998;82:1698-703.
57. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998;16:2018-24.
58. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
59. Fisher B. A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996;14:1027-39.
60. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL. Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
61. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125:493-501.
62. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992;11:105-16.
63. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosts in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9: 286-94.
64. 'Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988;57:608-11.
65. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R. et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract]. Proc Am Soc Clin Oncol 1998;17:2a.
66. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
67. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancel in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352: 98-101.
68. International classification of diseases. 9th rev. Clinical modification. 5th ed. Salt Lake City: Medicore Publications; 1997. p. 115-7.